Acta Scientific Paediatrics (ISSN: 2581-883X)

Case Report Volume 3 Issue 8

Efficacy and Safety of Anti-D for Acute Immune Thrombocytopenic Purpura in Children in El-Nasr Hospital - Case Report

Amal Shorbasy1, Heba Makki2* and Mustafa El Kahlout3

1Pharmacist, Masterin Pharmaceutical Sciences, El-Nasr Pediatric Hospital, Gaza,Palestine
2Pediatrician, Palestinian Board of Pediatrics, El-Nasr PediatricHospital, Gaza,Palestine
3Consultant Pediatrician, Palestinian Board of Pediatrics,Director of El Nasr Pediatric Hospital, Gaza, Palestine

*Corresponding Author: Heba Makki, Pediatrician, Palestinian Board of Pediatrics, El-Nasr PediatricHospital, Gaza, Palestine.

Received: March 25, 2020; Published: July 09, 2020



Immune (idiopathic) thrombocytopenic purpura (ITP) of childhood is characterized by acquired thrombocytopenia. ITP seems to occur more often after a viral respiratory illness. Findings on physical examination are normal, other than the finding of petechiae and purpura. Anti-D is effective in the treatment of children with ITP (Rh-positive non-splenectomized patients) and with higher doses appears to have comparable results to IVIG. Our experience in treating children with ITP in Gaza strip hospitals is restricted to use of corticosteroids or IVIG. No published clinical trial on safety and efficacy of anti-D in acute ITP in children in the Gaza strip. Four cases (2 males and 2 females) were admitted to El-Nasr Pediatric hospital during the period from April 2017 to December 2017 and all of them were diagnosed as acute ITP. The youngest patient was 1 year and 10 months old and the oldest patient was 11 years. Clinical presentation included skin rash 3 caseswith oral cavity bleeding in one case. All cases had history of previous URTI 1-2 weeks before the attack of ITP.Anti-D was used for allthese cases. Dose given was 50-75mic/kg. The overall response rate was 75%, three cases showed good response and platelet count was elevated within 24 hours. The duration of hospitalization for all the responsive cases was 2 days. No side effects of Anti- D were noted.

Conclusion:Anti-D is used in pediatric age group for use in some carefully selected cases of acute ITP. Anti-D showed nearly the same efficacy and safety with cost effectiveness comparable to IVIG.

Keywords: Idiopathic Thrombocytopenic Purpura; Anti-D; IVIG



Citation: Heba Makki.,et al. “Efficacy and Safety of Anti-D for Acute Immune Thrombocytopenic Purpura in Children in El-Nasr Hospital - Case Report". Acta Scientific Paediatrics 3.8 (2020): 02-05.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is March 30, 2023.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US